跳至主要内容
临床试验/EUCTR2011-001518-33-GB
EUCTR2011-001518-33-GB进行中(未招募)1 期

A signal seeking window trial of AZD8931 in patients with resectable non-small cell lung cancer - Window Trial of AZD8931 in resectable non-small cell lung cancer

niversity Hospital of South Manchester NHS Foundation Trust0 个研究点目标入组 20 人开始时间: 2012年7月30日最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Age 18 years or older.
  • Histologically confirmed NSCLC
  • Operable disease as determined by local staging investigations, including CT scan of thorax and abdomen, FDG-PET scan and mediastinoscopy where indicated as a standard of care.
  • Availability of surplus diagnostic biopsy tissue
  • WHO performance status 0 or 1
  • Haematology (These measurements must be performed within two weeks prior to the patient going on study):
  • Haemoglobin (Hb) > 9 g/dl
  • Neutrophils > 1.5 x 10 9/L
  • Platelets > 100 x 109/L
  • Partial thromboplastin time (PTT) and Prothrombin time (PT) < 1.5 x ULN
  • Hepatic function
  • Serum bilirubin < 1.5 x upper limit of normal (ULN)
  • Alanine amino-transferase (ALT) and/or aspartate amino-transferase (AST) < 2.5 X ULN
  • Adequate renal function (calculated clearance > 50 ml/min as per calculated Cockcroft formula
  • Ability to give written informed consent according to ICH/GCP, and national/local regulations.
  • Ability to co-operate with study treatment and follow up
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 0
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • Pregnancy. Only women of NONE child bearing potential may enter the study. Women must be permanently or surgically sterilized or postmenopausal* (see protocol for definitions).
  • Previous systemic treatment, radiotherapy or surgery for current lung cancer
  • Serious pre-existing medical co-morbidities, e.g. uncontrolled diabetes mellitus, uncontrolled respiratory or cardiac disease or ongoing or active infection (including HIV)
  • Psychiatric illness and/or social situation that would preclude study compliance
  • Prior (within the past 2 years) or concurrent malignancy (except adequately treated non-melanomatous skin cancer and resected cervical carcinoma in situ)
  • Baseline resting ECG with measurable QTc interval >480msec.
  • Echocardiogram confirming inadequate left ventricular function, LV ejection fraction<45%.
  • Known uncontrolled or symptomatic angina, arrhythmias or congestive heart failure, evidence of transmural infarction on ECG, poorly controlled hypertension (systolic >180 mmHg or diastolic >100 mmHg), significant valvular disease or history of high risk dysrrhythmia (such as ventricular fibrillation or ventricular tachycardia [includes ventricular triplets])
  • Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
  • Significantly impaired visual acuity
  • Medication that induces or inhibits CYP3A4 or reduces gastric acid production unless medically indicated

研究者

发起方
niversity Hospital of South Manchester NHS Foundation Trust

相似试验